Dominance of CTX-M group 1 beta-lactamase enzymes in ESBL producing E. coli from outpatient urines in neighboring regions of Austria and Italy.
The importance of extended spectrum β-lactamases (ESBL) is increasing worldwide. ESBLs of the CTX-M type are on the rise in Europe, not only in the hospital environment but also in outpatients. Therefore we performed a comparative pilot study including ESBL producing Escherichia coli isolated from outpatients suffering from urinary tract infections, 28 from Innsbruck, Austria, and 34 from Bolzano, Italy. Using established PCR methods we detected in nearly 90% of ESBL producing E. coli isolates CTX-M group 1 enzymes and only a few group 2 or group 9 enzymes. bla (TEM), bla (OXA-1) and aminoacyltransferase aac(6')-lb were significantly more frequent in the Austrian region, where also bla (SHV )was found in one isolate. In 2009 the overall prevalence of ESBL in E. coli causing urinary tract infection in outpatient samples was 7.6% in a local laboratory in Innsbruck and 5% in Bolzano. Additionally, we investigated plasmid-mediated qnr genes which can contribute to quinolone resistance, qnrA was found in an AmpC producing E. coli from Innsbruck and qnrS in two ESBL producers from Bolzano. Data confirmed that ESBL-producing E. coli have emerged as important pathogens in urinary tract infections of outpatients in both regions.
Department of Hygiene, Microbiology & Social Medicine, Medical University Innsbruck, Innsbruck, Austria. hartwig.huemer@i-med.ac.at
Hartwig P
HP
Huemer
Angelika
A
Eigentler
Richard
R
Aschbacher
Clara
C
Larcher
D001317:Austria; D004926:Escherichia coli / Q000201:enzymology* / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D007558:Italy; D014552:Urinary Tract Infections / Q000175:diagnosis / Q000382:microbiology* / Q000652:urine*; D001618:beta-Lactamases / Q000652:urine*
C055184:beta-lactamase TEM-3; D001618:beta-Lactamases
J Antimicrob Chemother. 2006 Jan;57(1):154-5
16284100
J Clin Microbiol. 2006 May;44(5):1659-64
16672390
Clin Microbiol Infect. 2010 Jul;16(7):934-44
19686277
Curr Med Chem. 2009;16(8):1028-46
19275610
Scand J Infect Dis. 2008;40(5):355-62
17934979
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:104-10
18154533
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:33-41
18154526
Antimicrob Agents Chemother. 2009 Feb;53(2):639-45
19064896
Antimicrob Agents Chemother. 2006 Nov;50(11):3953-5
16954321
Antimicrob Agents Chemother. 2005 Feb;49(2):801-3
15673773
Lancet. 1998 Mar 14;351(9105):797-9
9519952
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:144-53
18154538
Antimicrob Agents Chemother. 2006 Feb;50(2):785-7
16436746
Antimicrob Agents Chemother. 2009 Feb;53(2):603-8
19029321
J Clin Microbiol. 2006 Jan;44(1):241-3
16390981
Infection. 2008 Aug;36(4):362-7
18574554
Antimicrob Agents Chemother. 2006 Apr;50(4):1178-82
16569827
Clin Microbiol Infect. 2011 Feb;17(2):181-9
20345467
J Antimicrob Chemother. 2007 Nov;60(5):913-20
17848376
J Antimicrob Chemother. 2008 Mar;61(3):515-23
18184647
J Clin Microbiol. 2007 Apr;45(4):1167-74
17287329